Taking a lesson from JAK2 V617F-positive ET, if we can keep JAK2 V617F MAB less than 50% in PV, we may not need do anything further, so long as the appropriate sex-specific hematocrit values are maintained, since prolonged interferon therapy has its own deleterious organ-specific effects. The gene discussed is JAK2; the disease is essential thrombocythemia.